New cancer drug enters first human trials

NCT ID NCT05720117

Summary

This is the first study in people to test a new cancer drug called PYX-201. Researchers want to find a safe and effective dose for adults with advanced solid tumors that have spread or returned after other treatments. The study will also look for early signs that the drug can shrink tumors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cliniques Universitaires Saint-Luc

    RECRUITING

    Brussels, Brussels Capital, 1200, Belgium

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • HonorHealth Research Institute

    RECRUITING

    Scottsdale, Arizona, 85258, United States

  • Hospital Clínico Universitario de Valencia

    RECRUITING

    Valencia, València, 46010, Spain

  • Hospital Universitari Vall d'Hebrón

    RECRUITING

    Barcelona, Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, Madrid, 28041, Spain

  • Hospital Universitario HM Sanchinarro

    RECRUITING

    Madrid, Madrid, 28050, Spain

  • Institut Jules Bordet

    RECRUITING

    Brussels, Brussels Capital, 1070, Belgium

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • NEXT Dallas

    RECRUITING

    Dallas, Texas, 75231, United States

  • NEXT San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Rhode Island Hospital

    RECRUITING

    Providence, Rhode Island, 02903, United States

  • Ronald Reagan UCLA Medical Center

    RECRUITING

    Los Angeles, California, 90095, United States

  • SCRI - Florida Cancer Specialists

    RECRUITING

    Sarasota, Florida, 34232, United States

  • SCRI - HealthOne Denver

    RECRUITING

    Denver, Colorado, 80218, United States

  • START Madrid - Hospital Universitario Fundación Jiménez Díaz

    RECRUITING

    Madrid, Madrid, 28040, Spain

  • Sarah Cannon Research Institute London

    ACTIVE_NOT_RECRUITING

    London, England, W1G 6AD, United Kingdom

  • The Royal Marsden Hospital

    ACTIVE_NOT_RECRUITING

    London, England, SW3 6JJ, United Kingdom

  • The University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Universitair Ziekenhuis Antwerpen

    RECRUITING

    Edegem, Edegem, 2650, Belgium

  • Universitair Ziekenhuis Gent

    RECRUITING

    Ghent, Gent, 9000, Belgium

  • University College Hospital

    ACTIVE_NOT_RECRUITING

    London, England, NW1 2PG, United Kingdom

  • University of Chicago Medicine

    RECRUITING

    Chicago, Illinois, 60637, United States

  • University of Cincinnati Medical Center

    RECRUITING

    Cincinnati, Ohio, 45219, United States

  • University of Pennsylvania, Abramson Cancer Center

    RECRUITING

    Philadelphia, Pennsylvania, 19106, United States

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110-1010, United States

  • Winship Cancer Institute, Emory University

    RECRUITING

    Atlanta, Georgia, 30308, United States

Conditions

Explore the condition pages connected to this study.